FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 217 filers reported holding FATE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,480 | -99.6% | 8,717 | -99.2% | 0.00% | -100.0% |
| Q2 2023 | $5,120,088 | -20.1% | 1,075,649 | -4.4% | 0.00% | -25.0% |
| Q1 2023 | $6,411,976 | +224.7% | 1,124,908 | +474.8% | 0.00% | +100.0% |
| Q4 2022 | $1,974,542 | -61.5% | 195,693 | -14.5% | 0.00% | -50.0% |
| Q3 2022 | $5,130,000 | +1.9% | 228,896 | +12.7% | 0.00% | 0.0% |
| Q2 2022 | $5,035,000 | +278.3% | 203,170 | +491.7% | 0.00% | +300.0% |
| Q1 2022 | $1,331,000 | -78.7% | 34,337 | -67.8% | 0.00% | -66.7% |
| Q4 2021 | $6,242,000 | -37.9% | 106,678 | -37.1% | 0.00% | -50.0% |
| Q3 2021 | $10,048,000 | +87.5% | 169,522 | +174.5% | 0.01% | +100.0% |
| Q2 2021 | $5,359,000 | +16.8% | 61,750 | +10.9% | 0.00% | 0.0% |
| Q1 2021 | $4,589,000 | +147.1% | 55,665 | +172.5% | 0.00% | +200.0% |
| Q4 2020 | $1,857,000 | +452.7% | 20,424 | +143.2% | 0.00% | – |
| Q3 2020 | $336,000 | -95.4% | 8,398 | -96.1% | 0.00% | -100.0% |
| Q2 2020 | $7,334,000 | +518.9% | 213,744 | +300.5% | 0.01% | +500.0% |
| Q1 2020 | $1,185,000 | +136.5% | 53,374 | +108.7% | 0.00% | – |
| Q4 2019 | $501,000 | -63.2% | 25,575 | -70.8% | 0.00% | -100.0% |
| Q3 2019 | $1,361,000 | +64.4% | 87,685 | +114.8% | 0.00% | 0.0% |
| Q2 2019 | $828,000 | +172.4% | 40,813 | +135.5% | 0.00% | – |
| Q1 2019 | $304,000 | -66.6% | 17,330 | -75.6% | 0.00% | -100.0% |
| Q4 2018 | $910,000 | -26.9% | 70,941 | -7.2% | 0.00% | 0.0% |
| Q3 2018 | $1,245,000 | +112.1% | 76,418 | +47.7% | 0.00% | 0.0% |
| Q2 2018 | $587,000 | +487.0% | 51,724 | +402.3% | 0.00% | – |
| Q1 2018 | $100,000 | +212.5% | 10,298 | +98.3% | 0.00% | – |
| Q4 2017 | $32,000 | – | 5,193 | +7318.6% | 0.00% | – |
| Q3 2017 | $0 | – | 70 | -27.8% | 0.00% | – |
| Q2 2017 | $0 | – | 97 | -3.0% | 0.00% | – |
| Q1 2017 | $0 | – | 100 | +669.2% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 13 | -84.5% | 0.00% | – |
| Q2 2015 | $1,000 | -50.0% | 84 | -78.7% | 0.00% | – |
| Q3 2014 | $2,000 | – | 395 | +740.4% | 0.00% | – |
| Q4 2013 | $0 | – | 47 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |